A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks

NCT07519174 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

72

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Tacrolimus
DRUG: Crisaborole 2% Top Oint

Sponsor

Foundation University Islamabad

Collaborators

[object Object]